Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06200181 · ClinicalTrials.gov registry record · Phase 3
Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial
A Phase 3 study of Misuse, Opioid, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT06200181 is a Phase 3 study of Misuse, Opioid that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 87 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06200181, a Phase 3 study of Misuse, Opioid, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn about the effectiveness of taking the antipsychotic medication olanzapine to help lower opioid craving.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Olanzapine
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2024-04-02 |
| Est. Completion | 2026-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06200181
The ClinicalTrials.gov registry entry for NCT06200181 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Misuse, Opioid appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06200181 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06200181 about?
NCT06200181 is a clinical study titled "Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial". To learn about the effectiveness of taking the antipsychotic medication olanzapine to help lower opioid craving.
What is the current status of trial NCT06200181?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2024-04-02. Estimated completion is 2026-11-01.
What conditions does trial NCT06200181 study?
This clinical trial studies the following conditions: Misuse, Opioid.
What interventions are being tested in trial NCT06200181?
The interventions under investigation include: Placebo (DRUG), Olanzapine (DRUG).
Who is sponsoring clinical trial NCT06200181?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06200181 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.